Reference:	Date of data extraction:	Reviewer: KH
------------	--------------------------	--------------

PART 1: Study eligibility and characteristics of the study

	Exclusion criteria	Characteristics of the study	
Type of	☐ Not a peer-reviewed original research article, e.g.	-	
publication	commentary, editorial, letter, report, guidelines or		
	conference or meeting proceedings		
	□ Not published in English		
Study design/	☐ Case report	☐ Observational	☐ Retrospective
type of study	☐ Conceptual paper	☐ Intervention	☐ Prospective
	☐ Other:		☐ Cross-sectional
Data source	☐ Pre-existing material on drug-related morbidity	☐ Case records	
	without evaluation of drug-related morbidity in the	☐ Interview	
	current study	□ Reports	
		☐ Other:	
Setting	☐ Care unit(s) for patients with specific disease or	☐ Inpatient setting	☐ Africa
	disease class	☐ Outpatient setting	□ Eastern
		☐ Residential facility	Mediterranean
		☐ Community setting	□ Europe
		☐ Academic teaching facility	☐ North America
		☐ Other setting:	☐ South America
			☐ South-East Asia
		☐ No setting restrictions	☐ Western Pacific
Sampling	Sampling frame represents patients	☐ Health facility	
frame	□ with a certain medical condition	☐ Insurance scheme	
	☐ receiving a certain treatment, preventive health	☐ Population-based	
	intervention or procedure		
Characteristics	Participants	Sex:	Age group:
of participating	□ with a certain disease, disease class, symptom or	□ Male	$\square \leq 17$ years
patients	other medical condition	☐ Female	☐ 18-65 years
	☐ receive a certain treatment, e.g. specific	□ Both	□ ≥66 years
	medication, medication group, herbal product,		☐ No age limitation
	vaccine or medical procedure		
	□ receive a certain preventive health intervention or		
	diagnostic procedure		
Outcome	Do <u>not represent</u>	Prevalence/incidence/frequency of	e e
measures and	☐ Prevalence/incidence/frequency of drug-related	morbidity (or synonymous concep	
results	morbidity (or synonymous concepts)	☐ Mentioned as an outcome meas	
	☐ Preventability of drug-related morbidity	□ Not mentioned as an outcome n	neasure, but can be
	Represent exclusively	interpreted	1 * 1*.
	potential, not actual, morbidity	Preventability of drug-related mor	=
	specific medical conditions	☐ Mentioned as an outcome measure	
	☐ effects of chemical compounds (other than	☐ Not mentioned as an outcome n	neasure, but can be
	medicines), human transmitters, nutrients, nutritional	interpreted	
	product, alcohol, tobacco or illicit substances		
	pharmacodynamic, pharmacokinetic or		
	pharmacogenetic measures		
		ARTICLE EXCLUDED	_
	□ None of the exclusion criteria fulfilled →	ARTICLE INCLUDED →	proceed to page 2

Reference:	Date of data extraction	on: Reviewer: <u>KH</u>		
· · · · · · · · · · · · · · · · · · ·		bility assessment of drug-related morbidity (DRM)		
Aim of the study	To various and provention	mily assessment of arag related mornially (2 mil)		
Definition(s) of drug-rela	ted morbidity (DRM)			
		$ce(s)$ \square Modified from reference(s) \square Own definition (no reference)		
☐ Adverse drug reaction (AD		Description (+ relevant references):		
☐ Drug-related morbidity(DR	RM)			
☐ Drug-related problem (DR)	P)			
☐ Medication error (ME)				
☐ Other:				
				
□ Not defined	□ No definition			
		ncy/causality of drug-related morbidity (DRM)		
Measurement:	Assessor(s):	Assessment of causality (medication therapy \rightarrow adverse outcome):		
☐ Incidence	☐ Researcher(s)	☐ According to reference(s) ☐ Modified from reference(s)		
☐ Prevalence	☐ Health professional(s)	☐ Own definition (no reference)		
☐ Other frequency measure:	☐ Computer programme	Description (+ relevant references):		
	☐ Other(s)			
	Describe:			
□ Not defined		-		
□ Not defined				
	□ Not defined	☐ Method not specified (no reference)		
Additional description, e.g.	information on <u>validity</u> or <u>re</u>			
• / 8				
		7		
Assessment method of pr				
Reference:	Assessor(s):	Description of the method:		
☐ Bates et al. 1993/1995 ☐ Chan et al. 2001	☐ Same as above ↑	☐ According to reference(s)☐ Modified from the reference(s)☐ Own method (no reference)		
☐ Dubois and Brook 1988	□ Researcher(s)□ Health professional(s)	Description (+ relevant references):		
☐ Hallas et al. 1990	☐ Other(s)	Description (Televant Televinees).		
☐ Hartwig et al. 1992	Describe:			
☐ Hepler and Strand 1990				
☐ Leape at al. 1995				
☐ Schumock and Thornton				

Additional description, e.g. information on validity or reliability testing:

□ Not defined

Additional notes

 \square Other reference:

□ No reference

1992

(Please continue writing here in case of shortage of space in any parts of the sheet.)

☐ Method not specified (no reference)

Reference:	Date of data extraction:	Reviewer: KH		
Standardising the assessme	nt process			
Performing pilot	Yes			
	No			
Use of operational manual/guidelines/protocol	Yes			
mandas gardenness protocor	No			
Assessors				
Profession	Pharmacist(s)			
	Physician(s)			
	Nurse(s)			
	Not reported			
Training for/ experienced in	assessment Yes			
	No	, 'J		
Number of assessors per cas	se 1			
	≥2			
	Not reported			
Blinding assessors	Yes			
(if multiple assessors, cat ≥2	No No			
Managing conflicting assess (if multiple assessors, cat ≥2				
(If multiple assessors, cat \(\geq 2\)	Discussion and reassessment, of	consensus not		
	required			
	One assessor interpretation det assessment	ermines		
	Additional assessor(s)			
	Not reported			
Evaluation of assessment m	nothad			
Reliability of preventability				
	Yes, reference to another articl	e		
	No			
Sensitivity of preventability	assessments Yes, reported in same article			
	Yes, reference to another articl	e		
	No			
Specificity of preventability	assessments Yes, reported in same article	Yes, reported in same article		

Yes, reference to another article

No